ArticleBMC infectious diseases2025

Correction: Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study).

Ivan Gentile et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.